Canandaigua National Corp’s Vertex Pharmaceuticals VRTX Stock Holding History

Canandaigua National Corp’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$369K	Buy	+827	New	+$386K	0.03%	259

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Canandaigua National Corp's VRTX Position: Q1 2026 in Review

Canandaigua National Corp opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2026: 827 shares worth $369K. The stake represents 0.03% of the portfolio and ranks #259 among its holdings.

1,691 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Canandaigua National Corp held 827 shares of Vertex Pharmaceuticals worth $369K as of Q1 2026.
Vertex Pharmaceuticals was a new Canandaigua National Corp position in Q1 2026.
Vertex Pharmaceuticals made up 0.03% of Canandaigua National Corp's portfolio in Q1 2026, its #259 holding.
1,691 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Canandaigua National Corp's 13F filing for Q1 2026, filed 8 Apr 2026.